{
    "clinical_study": {
        "@rank": "43726", 
        "arm_group": {
            "arm_group_label": "Topical cyclosporine", 
            "arm_group_type": "Experimental", 
            "description": "This is a single arm study of patients who have received allogeneic bone marrow transplants performed with a reduced intensity conditioning regimen and are candidates to receive topical cyclosporine to prevent ocular graft versus host disease"
        }, 
        "brief_summary": {
            "textblock": "Ocular Graft Versus Host Disease (OGVHD) is a serious potential complication of allogeneic\n      bone marrow transplants. The usual treatment is topical cyclosporine but when the treatment\n      is initiated the damage to the lacrimal glands has already taken place.\n\n      The present study aims to prevent OGVHD in reduced-intensity allogeneic hematopoietic\n      transplants by using topical cyclosporine immediately after the engraftment has been\n      achieved"
        }, 
        "brief_title": "Prevention of Ocular Graft-Versus Host Disease With Topical Cyclosporine in Recipients of Allogeneic Hematopoietic Stem Cell Transplants Performed With a Reduced Intensity Conditioning Regimen", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Ocular Graft Versus Host Disease", 
        "condition_browse": {
            "mesh_term": "Graft vs Host Disease"
        }, 
        "detailed_description": {
            "textblock": "The patient will start using topical cyclosporine immediately after engraftment has taken\n      place (around day 14-18 after the cell infusion) and will continue to receive it for one\n      year.\n\n      All >18 year old patients  receiving allogeneic stem cell transplants performed with a\n      reduced intensity conditioning regimen at our center are potential candidates for the study.\n\n      The purpose of the study is to evaluate the efficacy of topical cyclosporine in prevention\n      of ocular versus graft disease when its use is indicated immediately after the engraftment\n      has occured."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who have written consent wishing to participate in the study\n\n          -  Patients who have received an allogeneic stem cell hematopoietic transplants\n             performed with a reduced intensity conditioning regimen\n\n          -  >18 year old\n\n        Exclusion Criteria:\n\n          -  <18 year old\n\n          -  Patients not wishing to participate in the study or have\n\n          -  Patients who have received autologous stem cell hematopoietic transplants\n\n          -  Patients with history of rheumatologic diseases\n\n          -  Patients with a previous diagnosis of dry eye syndrome"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02144025", 
            "org_study_id": "HU-EICHO"
        }, 
        "intervention": {
            "arm_group_label": "Topical cyclosporine", 
            "description": "Use of topical cyclosporine of ocular graft versus host disease prevention", 
            "intervention_name": "Topical Ocular Cyclosporine", 
            "intervention_type": "Drug", 
            "other_name": [
                "Topical ocular cyclosporine", 
                "modusik A ofteno Brand"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ocular Graft Versus Host Disease", 
            "Topical Cyclosporine"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "location": {
            "contact": {
                "email": "buhomike@hotmail.com", 
                "last_name": "Miguel Angel Herrera, Dr", 
                "phone": "(52)86756718"
            }, 
            "facility": {
                "address": {
                    "city": "Monterrey", 
                    "country": "Mexico", 
                    "state": "Nuevo Leon", 
                    "zip": "64460"
                }, 
                "name": "Servicio de Hematologia Hospital Universitario Dr Jose Eleuterio Gonzalez"
            }, 
            "investigator": [
                {
                    "last_name": "Olga Graciela Cantu-Rodriguez, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Juan Luis Gonzalez-Trevi\u00f1o, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Alberto Vazquez-Mellado", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "1", 
        "official_title": "Prevention of Ocular Graft-Versus Host Disease With Topical Cyclosporine in Recipients of Allogeneic Hematopoietic Stem Cell Transplants Performed With a Reduced Intensity Conditioning Regimen", 
        "overall_contact": {
            "email": "ogrcantu@yahoo.com.mx", 
            "last_name": "Olga Graciela Cantu-Rodriguez, PhD", 
            "phone": "(52)83486136"
        }, 
        "overall_contact_backup": {
            "email": "vmelladol@hotmail.com", 
            "last_name": "Alberto Vazquez, Dr", 
            "phone": "(52)83488510"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Mexico: Coordinaci\u00f3n de Investigaci\u00f3n en Salud", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The patient will start using ocular topical cyclosporine at the day of engraftment (around 14-16 days after cell infusion) and will continue to use it for one year.\nThe following landmarks will be evaluated:\nFirst evaluation of a new patient with the ophtalmologist: The patient will be evaluated by a qualified ophtalmologist before the allogeneic stem cell transplant with the following tests: Corneal integrity (yes or no), Schirmer test (mm), tear break up time (seconds).\nImmediately after engraftment has occured (around 14-16 days after cell infusion) the patient will start using topical cyclosporine and will continue to use it for one year.\nThere will be monthly evaluations with Schirmer test to asses tear quiality and detect dry eye syndrome.\nEvery three months the patient will have a complete optalmologic evaluation as describe before", 
            "measure": "Ocular graft versus host disease is manifested by dry eye syndrome and disruptions in corneal integrity. The study will asses the efficacy of topical cyclosporine for preventing OGVHD manifestations", 
            "safety_issue": "Yes", 
            "time_frame": "1 year after engraftment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02144025"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Universitario Dr. Jose E. Gonzalez", 
            "investigator_full_name": "Dra. Olga Graciela Cantu Rodriguez", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The secondary outcome of the study is to asses the clinical characteristics of ocular graft versus host disease in patients receiving allogeneic stem cell transplants performed with a reduced intensity conditioning regimen", 
            "measure": "Characteristics and clinical presentation of ocular graft versus host disease in patients receiving allogeneic bone marrow transplantation using a reduced intensity conditioning regimen", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "source": "Hospital Universitario Dr. Jose E. Gonzalez", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital Universitario Dr. Jose E. Gonzalez", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}